Challenges to National Cancer Institute-Supported Cooperative Group clinical trial participation: An ASCO survey of cooperative group sites

Journal of Oncology Practice

Volumn 6, Issue 3, 2010, Pages 114-117

  Baer, Allison R ^a   Kelly, Chelsey A ^a   Bruinooge, Suanna S ^a   Runowicz, Carolyn D ^a   Blayney, Douglas W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; RALOXIFENE; TAMOXIFEN; TAMOXIFEN CITRATE; TRASTUZUMAB;

ALLELE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; COMMUNITY CARE; COMPARATIVE EFFECTIVENESS; DRUG INDUSTRY; EVIDENCE BASED MEDICINE; FUNDING; GASTROINTESTINAL STROMAL TUMOR; HEALTH SURVEY; HUMAN; INTERNATIONAL COOPERATION; KIDNEY CARCINOMA; LUNG CANCER; NATIONAL HEALTH ORGANIZATION; OVARY CANCER; PANCREAS CANCER; PHILADELPHIA CHROMOSOME POSITIVE CELL; POPULATION RESEARCH; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; RECURRENCE RISK; REIMBURSEMENT; RISK ASSESSMENT; TREATMENT INDICATION;

EID: 77956593989     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.200028     Document Type: Article

References (18)

1. Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623-631, 2000
2. Cairncross G, Berkey B, Shaw E, et al: Phase III trials of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714, 2006
3. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
4. Genentech: Herceptin: Joint Analysis of NSABP B-31 and NCCTG. http://www.herceptin.com/hcp/adjuvant-treatment/studies-efficacy/joint-analysis. jsp
5. National Cancer Institute: Cancer Drug Decreases Recurrence of Gastrointestinal Stromal Tumors. http://www.cancer.gov/aboutnci/servingpeople/ gist
6. DeMatteo RP, Ballman KV, Antonescu CR, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 373:1097-1104, 2009
7. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
8. National Cancer Institute: Bevacizumab (Avastin) Questions and Answers. http://www.cancer.gov/cancertopics/factsheet/therapy/avastin
9. National Cancer Institute: The Breast Cancer Prevention Trial - Introduction. http://www.cancer.gov/clinicaltrials/digestpage/BCPT
10. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295:2727-2741, 2006
11. National Cancer Institute: Results of the Study of Tamoxifen and Raloxifene (STAR) Released: Osteoporosis Drug Raloxifene Shown to be as Effective as Tamoxifen in Preventing Invasive Breast Cancer. http://www.cancer.gov/newscenter/pressreleases/STARresultsApr172006
12. Finn R: Oncologist's role critical to clinical trial enrollment. J Natl Cancer Inst 92:1632-1634, 2000
13. Emanuel EJ, Schnipper LE, Kamin DY, et al: The costs of conducting clinical research. J Clin Oncol 21:4145-4150, 2003
14. C-Change: A Guidance Document for Implementing Effective Cancer Clinical Trials Executive Summary: Version 1.2. http://www.c-changetogether.org/pubs/ reports/GuidanceDocument-ES.pdf
15. National Cancer Institute: Cooperative Group Accrual Patterns. Bethesda, MD, National Institutes of Health, 2009
16. Comis RL: Improving the quality of cancer clinical trials. Presented at the Institute of Medicine National Cancer Policy Forum, Washington, DC, October 4-5, 2007
17. Bureau of Labor Statistics: Consumer Price Index Inflation Calculator. http://www.bls.gov/data/inflation-calculator.htm
18. National Institutes of Health: FY 2009 Enacted Appropriation. http://officeofbudget.od.nih.gov/pdfs/FY09/Final%20Conference.pdf